Immutep Ltd (ASX:IMM, NASDAQ:IMMP) is focused on the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease.
The company's current lead product candidate is eftilagimod alpha, a soluble LAG-3 fusion protein (LAG-3Ig).